Search Within

Shreya Vemuri

Formats
  1. Meeting Abstract (11)
  2. Journal Article (6)
Groups
  1. Department of Medicine (17)
  2. Center for Hematologic Malignancies (14)
  3. Hematologic Malignancies, Division of (14)
  4. Epidemiology and Biostatistics (10)
  5. Population Sciences Research Program (9)
  6. Survivorship Research (9)

More Groups

People
  1. Jae Park (7)
  2. Martin Tallman (7)
  3. Andrew Zelenetz (6)
  4. Ariela Noy (6)
  5. Matthew Matasar (6)
  6. Connie Batlevi (5)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (4)
  5. 2020 (3)
  6. 2019 (2)

More Years

Publications
  1. Blood (11)
  2. Journal of Clinical Oncology (3)
  3. Haematologica (1)
  4. JCO Global Oncology (1)
  5. NEJM Evidence (1)
Publishers
  1. American Society of Hematology (11)
  2. American Society of Clinical Oncology (4)
  3. Ferrata Storti Foundation (1)
  4. Massachusetts Medical Society (1)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Biospecimen repositories in low- and middle-income countries: Insights from an American University of Beirut and Memorial Sloan Kettering collaboration
    Journal Article

    Faraj, W.; Robson, M.; Tawil, A.; Reuter, V.; Mahfouz, R.; Cambria, R.; Saheb, N.; Ferrer, C. S.; Vemuri, S.; Yaghi, M.; more...
    JCO Global Oncology (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Journal Article

    Handa, S.; Lee, J. O.; Derkach, A.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Shukla, M.; Vemuri, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J. R.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Copley, D.; Grieve, C.; Jacob, A. P.; Joseph, A.; Laraque, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Journal Article

    Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Vemuri, S.; Flynn, J.; Hsu, M.; Devlin, S. M.; Roshal, M.; Gao, Q.; Shukla, M.; more...
    Haematologica (2021)

    Fulltext@MSK | Save